"Tempus AI" for smart diagnosis applies to the offer on the US Stock Exchange

Tempus AI Inc., a technology platform that uses artificial intelligence to process medical data, which applied for the initial public subscription, to participate in the wave of businesses offering their shares for public subscription while promoting their capabilities in the field of artificial intelligence. According to the deposit -referral supplied to the US Security and Exchange Committee on Monday, the company wants to provide ‘smart diagnoses’ for exact medicines. Timbus AI did not provide the first public entry details such as the offer price, which will later be included in the leaves. ‘Timbus AI’, based in Chicago, entered into a $ 266 million net loss of $ 532 million in 2023, compared to a net loss of $ 334 million in revenue of $ 321 million in the previous year, according to deposit newspapers. Deposits show that the ‘Timbus AI’ platform, founded in 2015, connects the laboratory results with the patient’s clinical data, and by more than 7,000 doctors in hundreds of networks for service providers, and a team that works about 2,300 employees, 250 of which medical or doctoral degree. One of the biggest investors in the business is Erik Livkovsky, founder and CEO, as well as a company controlled by Kimberly Kewell, and Balilie Gifford & Co. The offer is led by “Morgan Stanley”, “GB Morgan” and “Allen & Co”. The company plans to trade its shares in Nasdaq Global Select Market under the symbol “TM” (TEM).